The Effect of Physical Fatigue on Lower Limb Functional Performance Tests in a Healthy Population

February 5, 2020 updated by: Romain Meeusen, Vrije Universiteit Brussel

The Influence of Acute Physical Fatigue on Functional Performance Tests of the Lower Limb in a Healthy Population

The main objective of this project is:

1. To assess the influence of physical fatigue on a return-to-play test battery in a healthy population. In a later stage, these experiments could be carried out in a clinical context (e.g. in an ankle sprain population).

The researchers will use a randomized, placebo controlled, counter-balanced, cross-over design. Twenty healthy subjects will visit the lab 3 times. On the first visit (familiarisation trial), the investigators will collect the participants' characteristics. The participants will also be familiarized to the procedures and materials of the experiment during this first visit. The second and third visit contain the experimental setup and will proceed as follows: first, the participants will fill in a pre-test checklist, a mental fatigue scale (M-VAS) and motivation scale. In the mean time a little blood will be collected from the ear lobe to determine lactate and glucose levels; also, blood pressure will be checked. Next, the subjects will carry out a functional test battery (hop test, vertical jump test, Y-balance test, and a balance reaction-time test). Session rate of perceived exertion (SRPE) is measured to indicate how fatigued the participants feel due to the test battery; also, M-VAS is collected once more, as well blood lactate, glucose and blood pressure. These measures are followed by either a physical fatigue inducing task (Modified 30 seconds Wingate protocol) or time-matched control task (sitting on the bike without pedalling). Afterwards, researchers will collect blood lactate, glucose and blood pressure two times more; participants have to fill in M-VAS (2x), perform the same test battery, and fill in the SRPE scale one more time.

Heart frequency will be measured continuously during the trials.

Study Overview

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Brussels, Belgium, 1050
        • Vrije Universiteit Brussel

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy (No neurological/cardiorespiratory/psychological/musculoskeletal disorders)
  • Male and female
  • No medication
  • Non-smoker
  • Between 18 and 35 years old

Exclusion Criteria:

  • Back and/or lower extremity injuries during the past 6 months
  • Bone/joint abnormalities
  • Dizziness, history of loss of consciousness, any inner ear disorders
  • Nervous system disorders or dysfunctions
  • Uncorrected eye disorders/dysfunctions
  • Illness
  • Use of medication or any kind of drugs
  • Use of alcohol, caffeine and heavy efforts 24 hours before each trial
  • Not eating the same meal the night before and the morning of each experimental trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Control Condition
time-matched task (sitting on the bike without pedalling)
Experimental: Physical Fatigue Condition
Maximal cycling effort for 30s (Wingate modified)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Single-leg hop test
Time Frame: Change in single-leg hop test for distance performance: from baseline and 20 minutes after baseline (immediately after the assigned interventions)
Single-leg hop test for distance performance
Change in single-leg hop test for distance performance: from baseline and 20 minutes after baseline (immediately after the assigned interventions)
Vertical jump test
Time Frame: Change in vertical jump height performance: from baseline and 20 minutes after baseline (immediately after the assigned interventions)
Vertical jump height performance
Change in vertical jump height performance: from baseline and 20 minutes after baseline (immediately after the assigned interventions)
Y-balance test
Time Frame: Change in Y-balance performance: from baseline and 20 minutes after baseline (immediately after the assigned interventions)
Balance and reach performance; participants have to maintain their balance while reaching as far as possible along 3 different directions.
Change in Y-balance performance: from baseline and 20 minutes after baseline (immediately after the assigned interventions)
Balance-reaction time test
Time Frame: Change in balance and reaction time performance: from baseline and 20 minutes after baseline (immediately after the assigned interventions)
Balance and reaction time performance; participants have to maintain their balance while reacting as fast as possible in 3 different directions.
Change in balance and reaction time performance: from baseline and 20 minutes after baseline (immediately after the assigned interventions)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mental fatigue Visual Analogue Scale (M-VAS)
Time Frame: Change in M-VAS: at baseline, 10 min after baseline (immediately after the first test battery), 15 min after baseline (immediately after the assigned interventions) and 25 min after baseline (immediately after the final test battery)
Subjective measure of mental fatigue (0-10cm; 0 = no mental fatigue; 10 = maximal mental fatigue)
Change in M-VAS: at baseline, 10 min after baseline (immediately after the first test battery), 15 min after baseline (immediately after the assigned interventions) and 25 min after baseline (immediately after the final test battery)
Perception of effort (Session RPE)
Time Frame: Change in session RPE: at baseline (immediately after the first test battery), 15 min after baseline (immediately after the final test battery)
Subjective measure of effort after completion of the test battery (scale from 0 to 10; 0 = very very easy; 10 = maximal effort)
Change in session RPE: at baseline (immediately after the first test battery), 15 min after baseline (immediately after the final test battery)
Self-reported motivation
Time Frame: At baseline: prior to the first test battery
Subjective measure of motivation assessed with the self-reported Motivation scale of Matthews et al.. (the questionnaire measures 2 constructs: intrinsic motivation and task succes motivation;the questionnaire comprises 14 questions scored from 0 to 4 [0 = not all motivated, while 4 = maximally motivated]. Each construct contains 7 questions).
At baseline: prior to the first test battery
Blood lactate
Time Frame: Change in blood lactate: at baseline, 10 min after baseline (immediately after the first test battery), 15 min after baseline (immediately after the assigned interventions) and 25 min after baseline (immediately after the final test battery)
Capillary blood will be collected at the ear lobe for the determination of blood lactate (determined enzymatically)
Change in blood lactate: at baseline, 10 min after baseline (immediately after the first test battery), 15 min after baseline (immediately after the assigned interventions) and 25 min after baseline (immediately after the final test battery)
Blood glucose
Time Frame: Change in blood glucose: at baseline, 10 min after baseline (immediately after the first test battery), 15 min after baseline (immediately after the assigned interventions) and 25 min after baseline (immediately after the final test battery)
Capillary blood will be collected at the ear lobe for the determination of blood glucose concentration
Change in blood glucose: at baseline, 10 min after baseline (immediately after the first test battery), 15 min after baseline (immediately after the assigned interventions) and 25 min after baseline (immediately after the final test battery)
Blood pressure
Time Frame: Change in blood pressure: at baseline, 10 min after baseline (immediately after the first test battery), 15 min after baseline (immediately after the assigned interventions) and 25 min after baseline (immediately after the final test battery)
Objective measure of blood pressure via eletronic blood pressure measuring device
Change in blood pressure: at baseline, 10 min after baseline (immediately after the first test battery), 15 min after baseline (immediately after the assigned interventions) and 25 min after baseline (immediately after the final test battery)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Romain Meeusen, Professor, Vrije Universiteit Brussel

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 19, 2019

Primary Completion (Actual)

February 3, 2020

Study Completion (Actual)

February 3, 2020

Study Registration Dates

First Submitted

July 18, 2019

First Submitted That Met QC Criteria

July 22, 2019

First Posted (Actual)

July 23, 2019

Study Record Updates

Last Update Posted (Actual)

February 6, 2020

Last Update Submitted That Met QC Criteria

February 5, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 143201939779

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Return to Sport

Clinical Trials on Physical Fatigue

3
Subscribe